Celecoxib and Erlotinib in Treating Patients With Liver Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib and erlotinib may stop the growth of tumor cells by blocking some of the
enzymes needed for their growth. Celecoxib may also stop the growth of liver cancer by
blocking blood flow to the tumor.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving celecoxib
together with erlotinib and to see how well they work in treating patients with liver cancer.